立体定向放疗同步治疗寡转移肺癌伴脑转移
本研究回顾2004年6月至2016年1月数据库,筛选cT1-2aN0M1非小细胞肺癌伴1-3个同步脑转移、接受肺部SBRT和脑SRS的6例患者,中位随访9个月,中位OS 12.4个月,1年OS 67%、FFP 17%、LC 100%,脑病灶1年LC 80%。
要点
- 同步肺部SBRT和脑SRS对寡转移NSCLC伴脑转移患者可获得100%的1年局部控制。
- 中位OS为12.4个月,1年OS为67%,但1年FFP仅17%。
- 脑病灶1年LC为80%、1年FFP为53%,远处进展常见。
核心结论
- 对于转移灶局限于脑的寡转移肺癌患者,肺部SBRT联合脑SRS可实现所有部位的良好局部控制,并带来令人鼓舞的OS。
研究设计与样本
- 回顾性数据库分析,纳入2004年6月至2016年1月接受肺部SBRT和脑SRS的cT1-2aN0M1 NSCLC伴脑转移患者6例。
主要发现
- 6例患者有1-3个同步脑转移,无人接受免疫治疗,三分之二未接受全身治疗。
- 中位随访9个月(范围2-95个月),存活患者随访95个月。
- 中位OS为12.4个月(95%CI 7-18个月)。
- 1年OS为67%(95%CI 29-100%),1年FFP为17%(95%CI 0-46%),1年LC为100%。
- 脑病灶1年LC为80%(95%CI 45-100%),1年FFP为53%(95%CI 5-100%)。
临床怎么用
- 对寡转移NSCLC伴同步脑转移患者,可考虑肺部SBRT联合脑SRS以获取良好的局部控制。
局限性
- 样本量仅6例,随访时间短,结论需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is increasing interest in treating oligometastatic non-small cell lung cancer (NSCLC) patients with stereotactic radiation. We aimed to address whether patients definitively treated with synchronous thoracic stereotactic body radiation therapy (SBRT) and brain stereotactic radiosurgery (SRS) had favorable outcomes with local therapy. MATERIALS AND METHODS: We reviewed a database of patients receiving lung SBRT as well as a database for brain metastasis patients treated with SRS between June 2004 and January 2016. We selected for cT1-2aN0M1 NSCLC patients with brain metastases and calculated their overall survival (OS), freedom from progression (FFP), and local control (LC) rates. RESULTS: Six patients had oligometastatic NSCLC with 1-3 synchronous brain metastases treated with lung SBRT and brain SRS. No patients received immunotherapy and two-thirds did not receive systemic therapy. Median follow-up was 9 months for the entire cohort (range, 2-95 months) and 95 months for the surviving patient. Median OS was 12.4 months (95% confidence interval [CI], 7-18 months). At 1 year, patients had 67% OS (95% CI, 29-100%), 17% FFP (95% CI, 0-46%), and 100% LC. Their brain disease had 80% 1-year LC (95% CI, 45-100%) and 53% 1-year FFP (95% CI, 5-100%). Two patients had no distant progression, two had brain progression, one had adrenal gland progression, and one had bone and liver progression. CONCLUSION: In patients presenting with oligometastatic lung cancer limited to the brain, treatment with both lung SBRT and brain SRS achieves good LC of all sites with encouraging OS.
引用
- Nikitas J, Roach M, Robinson C, et al. Treatment of oligometastatic lung cancer with brain metastases using stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT). Clin Transl Radiat Oncol. 2019. PMID: 31956701. doi:10.1016/j.ctro.2019.12.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。